絞り込み

16642

広告

Overexpression of Circulating Soluble Nogo-B Improves Diabetic Kidney Disease by Protecting the Vasculature.

著者 Hernandez-Diaz I , Pan J , Ricciardi CA , Bai X , Ke J , White KE , Flaquer M , Fouli GE , Argunhan F , Hayward AE , Hou FF , Mann GE , Miao RQ , Long DA , Gnudi L
Diabetes.2019 Jun 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (6view , 0users)

Full Text Sources

Miscellaneous

Molecular Biology Databases

Damage to the vasculature is the primary mechanism driving chronic diabetic microvascular complications such as diabetic nephropathy which manifests as albuminuria. Therefore, treatments that protect the diabetic vasculature have significant therapeutic potential. Soluble Neurite outgrowth inhibitor-B (sNogo-B) is a circulating N-terminus isoform of full-length Nogo-B which plays a key role in vascular remodelling following injury. However, there is currently no information on the role of sNogo-B in the context of diabetic nephropathy. We demonstrate that overexpression of sNogo-B in the circulation ameliorates diabetic kidney disease by reducing albuminuria, hyperfiltration, abnormal angiogenesis and protecting glomerular capillary structure. Systemic sNogo-B overexpression in diabetic mice also associates with dampening VEGF-A signalling and reducing eNOS, AKT and GSK3β phosphorylation. Furthermore, sNogo-B prevented the impairment of tube formation which occurred when human endothelial cells were exposed to sera from patients with diabetic kidney disease. Collectively, these studies provide the first evidence that sNogo-B protects the vasculature in diabetes and may represent a novel therapeutic target for diabetic vascular complications.
PMID: 31217174 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード